PriceTargets.com logo

Forte Biosciences - FBRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.13
  • Forecasted Upside: -97.45%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.11 As of 10/2/2024 01:00 AM ET
▼ -0.05 (-0.97%)

This chart shows the closing price for FBRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Forte Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FBRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FBRX

Analyst Price Target is $0.13
▼ -97.45% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Forte Biosciences in the last 3 months. The average price target is $0.13, with a high forecast of $0.16 and a low forecast of $0.11. The average price target represents a -97.45% upside from the last price of $5.11.

This chart shows the closing price for FBRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Forte Biosciences. This rating has held steady since July 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/11/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/19/2024Chardan CapitalReiterated RatingBuy ➝ Buy$0.12 ➝ $0.12
5/30/2024Brookline Capital ManagementInitiated CoverageBuy$0.16
4/8/2024LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$0.11
7/16/2023Chardan CapitalReiterated RatingNeutral
5/15/2023Chardan CapitalReiterated RatingNeutral
8/17/2022Chardan CapitalDowngradeBuy ➝ Neutral
9/3/2021Brookline Capital ManagementReiterated RatingHold
9/3/2021Brookline Capital AcquisitionDowngradeBuy ➝ Hold
9/3/2021FBR & Co.DowngradeBuy ➝ Hold
9/3/2021Truist FinancialDowngradeBuy ➝ Hold
9/3/2021LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
9/3/2021Chardan CapitalDowngradeBuy ➝ Sell
9/3/2021B. RileyDowngradeBuy ➝ Neutral
7/9/2021Chardan CapitalInitiated CoverageBuy$4.20
7/1/2021Chardan CapitalReiterated RatingBuy
5/14/2021B. RileyInitiated CoverageReduce ➝ Buy$2.92
3/26/2021FBR & Co.Initiated CoverageBuy
3/17/2021Chardan CapitalLower TargetBuy$4.60 ➝ $4.20
11/11/2020Chardan CapitalBoost Target$4.40 ➝ $4.60
9/24/2020Chardan CapitalBoost TargetBuy$2.40 ➝ $4.40
9/10/2020Chardan CapitalBoost TargetBuy$1.80 ➝ $2.40
8/28/2020Brookline Capital ManagementInitiated CoverageBuy$3.60
8/28/2020Chardan CapitalUpgradeNeutral ➝ Buy$1.80
8/28/2020FBR & Co.Initiated CoverageBuy
8/25/2020Truist FinancialInitiated CoverageBuy$2.80
6/22/2020LADENBURG THALM/SH SHInitiated CoverageBuy
(Data available from 10/3/2019 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/7/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/5/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/5/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/4/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Forte Biosciences logo
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Read More

Today's Range

Now: $5.11
Low: $4.89
High: $5.18

50 Day Range

MA: $3.46
Low: $0.00
High: $7.90

52 Week Range

Now: $5.11
Low: $4.86
High: $21.25

Volume

15,134 shs

Average Volume

3,373 shs

Market Capitalization

$186.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Forte Biosciences?

The following sell-side analysts have issued reports on Forte Biosciences in the last year: Brookline Capital Management, Chardan Capital, and LADENBURG THALM/SH SH.
View the latest analyst ratings for FBRX.

What is the current price target for Forte Biosciences?

3 Wall Street analysts have set twelve-month price targets for Forte Biosciences in the last year. Their average twelve-month price target is $0.13, suggesting a possible downside of 97.5%. Brookline Capital Management has the highest price target set, predicting FBRX will reach $0.16 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $0.11 for Forte Biosciences in the next year.
View the latest price targets for FBRX.

What is the current consensus analyst rating for Forte Biosciences?

Forte Biosciences currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FBRX will outperform the market and that investors should add to their positions of Forte Biosciences.
View the latest ratings for FBRX.

What other companies compete with Forte Biosciences?

Other companies that are similar to Forte Biosciences include Cue Biopharma, Enlivex Therapeutics, Surrozen, Pluri and Elevation Oncology. Learn More about companies similar to Forte Biosciences.

How do I contact Forte Biosciences' investor relations team?

Forte Biosciences' physical mailing address is 1124 W CARSON STREET MRL BUILDING 3-320, TORRANCE CA, 90502. The company's listed phone number is (310) 618-6994 and its investor relations email address is [email protected]. The official website for Forte Biosciences is www.fortebiorx.com. Learn More about contacing Forte Biosciences investor relations.